<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396250</url>
  </required_header>
  <id_info>
    <org_study_id>17934</org_study_id>
    <nct_id>NCT03396250</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects</brief_title>
  <official_title>An Open Label Crossover Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the relative bioavailability of Naproxen Sodium 220 mg and diphenhydramine&#xD;
      hydrochloride (DPH HCL) 25 mg soft capsules (Test) versus Naproxen Sodium 220 mg and&#xD;
      diphenhydramine hydrochloride 25 mg tablets (Reference) after a single oral administration&#xD;
      under fasted condition in healthy adults subjects.&#xD;
&#xD;
      To assess the safety and tolerability of the investigational products in terms of advent&#xD;
      events (AEs) and clinical parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">March 29, 2018</completion_date>
  <primary_completion_date type="Actual">March 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Within 30 minutes prior to dosing (baseline) 10, 20, 30, 45, 60 minutes and 1 hour 20 minutes, 1 hour 40 minutes, 2, 2 hours 30 minutes, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Area under the concentration vs. time curve from zero to infinity after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)</measure>
    <time_frame>Within 30 minutes prior to dosing (baseline) 10, 20, 30, 45, 60 minutes and 1 hour 20 minutes, 1 hour 40 minutes, 2, 2 hours 30 minutes, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Area under plasma concentration vs. time curve from zero to last data point &gt;LLOQ (lower limit of quantitation), calculated up by linear trapezoidal rule, down by logarithmic trapezoidal rule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Within 30 minutes prior to dosing (baseline) 10, 20, 30, 45, 60 minutes and 1 hour 20 minutes, 1 hour 40 minutes, 2, 2 hours 30 minutes, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Maximum observed drug concentration, directly observed from analytical data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Test product + Reference product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product + Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium and diphenhydramine hydrochloride soft capsules</intervention_name>
    <description>Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)</description>
    <arm_group_label>Reference product + Test product</arm_group_label>
    <arm_group_label>Test product + Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)</intervention_name>
    <description>Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)</description>
    <arm_group_label>Reference product + Test product</arm_group_label>
    <arm_group_label>Test product + Reference product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult men or women&#xD;
&#xD;
          -  Age 18 to 55 years inclusive;&#xD;
&#xD;
          -  Body mass index 18.5 to 30.0 kg/m2 inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity symptoms with the use of naproxen/naproxen sodium,&#xD;
             diphenhydramine hydrochloride/citrate, acetylsalicylic acid, other Nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or similar pharmacological agents or components of&#xD;
             the products;&#xD;
&#xD;
          -  Females who are pregnant or lactating;&#xD;
&#xD;
          -  Vegetarian or restricted diet (e.g., gluten-free);&#xD;
&#xD;
          -  Any active disease, acute or chronic;&#xD;
&#xD;
          -  Have taken naproxen/naproxen sodium, DPH HCl or diphenhydramine citrate, DPH HCl or&#xD;
             diphenhydramine citrate-containing products, acetylsalicylic acid (ASA),&#xD;
             ASA-containing products, acetaminophen, ibuprofen, any other NSAID (Over-the -counter&#xD;
             [OTC] or prescription) or NSAID containing products, xanthines, antihistamines or&#xD;
             caffeine-containing products (e.g. coffee, tea and chocolate) 7 days prior to dosing&#xD;
             or during the Dosing Periods, other than trial treatment;&#xD;
&#xD;
          -  Use of any over-the-counter or prescription medications, vitamins or herbal&#xD;
             supplements (except acceptable forms of birth control) within 7 days prior to dosing&#xD;
             or throughout the trial, unless in the opinion of the Investigator, the medication&#xD;
             will not interfere with the trial procedures, data integrity, or compromise the safety&#xD;
             of the subject;&#xD;
&#xD;
          -  Positive test for Human immunodeficiency virus (HIV) antibodies and antigens;&#xD;
&#xD;
          -  Positive test for hepatitis B surface antigen (HBsAg) test;&#xD;
&#xD;
          -  Positive test for anti-hepatitis C virus (Anti-HCV) antibodies;&#xD;
&#xD;
          -  In the judgment of the investigator, any need of other medication during the trial&#xD;
             besides the test and reference study medication;&#xD;
&#xD;
          -  Recently had (past 30 days) or plan to have surgery, an invasive procedure, tattoos or&#xD;
             piercings during the trial or within 2 weeks after treatment;&#xD;
&#xD;
          -  More than moderate alcohol consumption (&gt;40 g of alcohol regularly per day);&#xD;
&#xD;
          -  Positive alcohol or drug screen at Screening or on Day -1 of each dosing period.&#xD;
&#xD;
          -  Any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine,&#xD;
             opiates, methamphetamine or cannabis abuse;&#xD;
&#xD;
          -  Loss of blood in excess of 50 mL to 499 mL within 30 days or 500 ml within 56 days of&#xD;
             the first dose of trial treatment (e.g., donation, plasmapheresis or injury);&#xD;
&#xD;
          -  Excessive sports or sauna within 5 days before start of the treatment phase and&#xD;
             unwilling to abstain during the trial;&#xD;
&#xD;
          -  Have a platelet count &lt;150,000/mm3 and in the judgment of the investigator, presents a&#xD;
             significant bleeding risk;&#xD;
&#xD;
          -  History of gastrointestinal bleeding or perforation, related to previous NSAID&#xD;
             therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct&#xD;
             episodes of proven ulceration or bleeding);&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases&#xD;
             (including glaucoma or benign prostatic hypertrophy) or malignancies or any other&#xD;
             disease or condition which could influence the metabolism of the drug;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Development Solutions, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

